Scientific Publications

New Approaches to Target T-ALL.

Publication TypeJournal Article
AuthorsRoti, G., and Stegmaier K.
AbstractAcute lymphoblastic leukemia is the most common malignancy in children. Although it is now curable in 80-90% of cases, patients with T-cell acute lymphoblastic leukemia (T-ALL) experience a higher frequency of induction failure and early relapse. Despite aggressive treatment approaches, including transplantation and new salvage regimens, most children with relapsed T-ALL will not be cured. As such, we are in need of new targeted therapies for the disease. Recent advances in the molecular characterization of T-ALL have uncovered a number of new therapeutic targets. This review will summarize recent advancements in the study of inhibiting the NOTCH1, PI3K-AKT, and Cyclin D3:CDK4/6 pathways as therapeutic strategies for T-ALL. We will focus on pre-clinical studies supporting the testing of small-molecule inhibitors targeting these proteins and the rationale of combination therapies. Moreover, epigenetic approaches to modulate T-ALL are rapidly emerging. Here, we will discuss the data supporting the role of bromodomain and extra-terminal bromodomain inhibitors in human T-ALL.
Year of Publication2014
JournalFrontiers in oncology
Volume4
Pages170
Date Published (YYYY/MM/DD)2014/01/01
DOI10.3389/fonc.2014.00170
PubMedhttp://www.ncbi.nlm.nih.gov/pubmed/25072021?dopt=Abstract